Kura Oncology (KURA) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
Verastem (VSTM) has outperformed Kura Oncology (KURA) over the past year, losing 6.2% versus a loss of 7.7%. Over five years, KURA leads with a -48.3% price change compared with -71.7% for VSTM. Kura Oncology is the larger company by market cap ($807.8 million vs $783.4 million), about 1.0 times the size, while Verastem is growing revenue faster (+209.1% vs +25.2%).
Kura Oncology converts more of its revenue into profit, with a net margin of -412.9% versus -677.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KURA | VSTM |
|---|---|---|
| Share price | $9.08 | $8.65 |
| Market cap | $807.76M | $783.37M |
| 1-day change | -6.39% | -6.28% |
| YTD return | -12.61% | +12.05% |
| 1-year return | -7.72% | -6.18% |
| 5-year return | -48.29% | -71.73% |
| EPS (TTM) | $-3.37 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $67.48M | $30.91M |
| Revenue growth (YoY) | +25.24% | +209.14% |
| Net income (latest FY) | $-278.67M | $-209.47M |
| Operating margin | -449.94% | -550.33% |
| Net margin | -412.95% | -677.59% |
| 52-week high | $13.90 | $10.82 |
| 52-week low | $7.36 | $3.43 |
| Distance from 52-week high | -34.68% | -20.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +250.77% | +90.06% |
| Average volume | 1.82M | 3.05M |
| Shares outstanding | 88.96M | 90.56M |
| Employees | 260 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Kura Oncology is more profitable, keeping -412.9 cents of every revenue dollar as net income versus -677.6 cents for Verastem.
- Verastem grew revenue faster in its latest fiscal year (+209.14% vs +25.24%).
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
KURA vs VSTM FAQ
Which is bigger, Kura Oncology or Verastem?
Kura Oncology (KURA) is larger, with a market capitalization of $807.76M compared with $783.37M for Verastem (VSTM).
Which stock has performed better over the past year, KURA or VSTM?
VSTM returned -6.18% over the past 12 months, compared with -7.72% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Kura Oncology and Verastem in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.